AKUMS DRUGS AND PHARMA L Share Price

NSE: AKUMS

₹ 687.30

-₹8.60 (-1.24%)

Last updated 24 Jul, 2026, 15:43 IST

AKUMS DRUGS AND PHARMA L Share Price Today

As of 25 Jul 2026, AKUMS DRUGS AND PHARMA L share price is ₹687.30. The stock opened at ₹688.40, compared to its previous close of ₹695.90. During today's trading session, AKUMS DRUGS AND PHARMA L share price moved in the range of ₹678.10 to ₹692.90, with an average price of ₹685.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹409.30 and a high of ₹714.70. On the performance front, AKUMS DRUGS AND PHARMA L share price has increased by 61.79% over the last six months and is up 27.89% on a year-on-year basis.

₹678.10

1.24% down today

₹692.90

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 21.74% QoQ

Latest Earning

Net Profit TrendUp by 20.20% QoQ

Latest Earning

Revenue TrendUp by 7.61% YoY

Stock Performance

OutperformingBeat Nifty by 13.25 % in last 1 month

Shareholding Pattern

DIIDII increased stake by 7.97%

Shareholding Pattern

FIIFII increased stake by 39.12%

AKUMS DRUGS AND PHARMA L Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹6,48,152+₹1,48,152 (+29.63%)

3 Year

₹3,97,720-₹1,02,280 (-20.46%)

5 Year

₹3,97,720-₹1,02,280 (-20.46%)

₹626.35₹765.45

Circuit Low

Circuit High

₹409.30₹714.70

52-Week Low

52-Week High

Circuit

₹626.35

₹765.45

52-week

₹409.30

₹714.70

Mkt Cap Cr

10,772.00

P/E

27.96

P/B

2.15

ROE

8.06%

D/E

0.02

ROCE

12.53%

Div. Yield

0.63%

EPS(TTM)

7.29

Turnover

0.54

EV/EBITDA

8.90

Net Margin

8.28%

Op. Margin

15.12%

ROA

5.78%

Quick Ratio

3.60

Curr. Ratio

3.26

Mkt Cap Cr

10,772.00

P/E

27.96

P/B

2.15

ROE

8.06%

D/E

0.02

ROCE

12.53%

Div. Yield

0.63%

EPS(TTM)

7.29

Turnover

0.54

EV/EBITDA

8.90

Net Margin

8.28%

Op. Margin

15.12%

ROA

5.78%

Quick Ratio

3.60

Curr. Ratio

3.26

Based on fundamentals, this stock's

Performance

Excellent

Akums Drugs outperforming all market indices

Valuation

Overvalued

Akums Drugs appears overvalued compared to its peers

Earnings

Good

Akums Drugs revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

AKUMS DRUGS AND PHARMA L Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹4,359.02	₹4,118.16	₹4,178.18	₹3,654.82
Other Income	₹128.73	₹52.12	₹34.03	₹90.07
Total Revenue	₹4,487.74	₹4,170.28	₹4,212.21	₹3,744.89
Total Expenses	₹4,085.62	₹3,841.72	₹4,231.45	₹3,519.89
Profit Before Tax	₹382.10	₹345.25	-₹45.28	₹150.30
Tax	₹125.70	₹1.48	-₹46.07	₹52.48
Profit After Tax	₹256.40	₹343.78	₹0.79	₹97.82
EPS - Basic	₹16.67	₹22.60	-₹0.28	₹6.63
EPS - Diluted	₹16.67	₹22.60	-₹0.28	₹6.63

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹382.10	₹345.25	-₹45.28	₹150.30
Income before WC changes	₹546.36	₹512.96	₹510.81	₹308.03
Change in Assets	-₹205.31	-₹65.77	₹47.13	₹9.25
Change in Liabilities	₹927.52	₹99.24	₹2.74	-₹43.58
Change in WC	₹722.21	₹33.47	₹49.87	-₹34.33
Cash flow from Operations	₹1,181.20	₹465.20	₹498.26	₹176.63
Cash flow from Investing	-₹930.27	-₹547.84	-₹330.42	-₹304.70
Cash flow from Financing	₹33.88	₹72.79	-₹108.02	₹124.54
Total Cash Flow	₹284.81	-₹9.86	₹59.82	-₹3.53
Cash (Start of the year)	₹101.19	₹111.05	₹51.61	₹55.14
Cash (End of the year)	₹386.01	₹101.19	₹111.05	₹51.61

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹1,887.11	₹1,838.83	₹1,575.48	₹1,387.66
Current Assets	₹3,559.86	₹2,274.61	₹1,940.88	₹1,878.87
Total Assets	₹5,446.97	₹4,113.44	₹3,516.37	₹3,266.53
Current Liabilities	₹1,094.76	₹893.75	₹1,210.55	₹1,265.57
Net Current Asset	₹2,465.10	₹1,380.86	₹730.33	₹613.31
Non-Current Liabilities	₹1,021.09	₹156.08	₹1,585.33	₹1,277.59
Equity Capital	₹3,331.12	₹3,063.61	₹720.49	₹723.37
Total Equity & Liabilities	₹5,446.97	₹4,113.44	₹3,516.37	₹3,266.53

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹1,348.74	₹1,311.78	₹1,444.12	₹1,286.83
Other Income	₹112.97	₹124.19	₹94.12	₹96.15
Total Revenue	₹1,461.70	₹1,435.98	₹1,538.24	₹1,382.98
Total Expenses	₹1,306.82	₹1,228.14	₹1,621.78	₹1,088.13
Profit Before Tax	₹148.37	₹207.84	-₹102.93	₹150.32
Tax	₹36.73	₹46.84	₹62.52	₹24.89
Profit After Tax	₹111.64	₹161.00	-₹165.45	₹125.43
EPS - Basic	₹7.29	₹10.76	-₹11.56	₹8.77
EPS - Diluted	₹7.29	₹10.76	-₹11.56	₹8.77

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹148.37	₹207.84	-₹102.93	₹150.32
Income before WC changes	₹111.21	₹150.83	₹241.07	₹118.58
Change in Assets	-₹86.41	-₹24.94	₹42.78	₹23.14
Change in Liabilities	₹8.90	₹13.97	₹0.35	-₹106.13
Change in WC	-₹77.51	-₹10.96	₹43.12	-₹83.00
Cash flow from Operations	-₹2.15	₹91.00	₹247.91	₹94.01
Cash flow from Investing	-₹24.97	-₹458.84	-₹165.44	-₹202.17
Cash flow from Financing	-₹3.00	₹375.38	-₹20.74	₹89.90
Total Cash Flow	-₹30.11	₹7.54	₹61.72	-₹18.26
Cash (Start of the year)	₹76.49	₹68.96	₹7.23	₹25.49
Cash (End of the year)	₹46.38	₹76.49	₹68.96	₹7.23

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹1,488.98	₹1,851.73	₹1,562.18	₹1,373.13
Current Assets	₹1,323.50	₹833.18	₹533.24	₹521.08
Total Assets	₹2,812.48	₹2,684.91	₹2,095.43	₹1,894.21
Current Liabilities	₹304.00	₹309.31	₹501.74	₹496.56
Net Current Asset	₹1,019.50	₹523.87	₹31.50	₹24.53
Non-Current Liabilities	₹80.92	₹70.36	₹1,449.81	₹1,086.15
Equity Capital	₹2,427.57	₹2,305.25	₹143.88	₹311.50
Total Equity & Liabilities	₹2,812.48	₹2,684.91	₹2,095.43	₹1,894.21

* All values are in INR Crore

Qty

Bid

Ask

Qty

687.3

228

Bid Total: 0

Ask Total: 228

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bearish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

67.29

Neutral

ATR (14)

26.94

Neutral

STOCH(9,6)

70.83

Neutral

STOCH RSI (14)

37.16

Neutral

ADX(9)

46.32

Bearish

UO(9)

53.61

Neutral

ROC(12)

7.09

Bullish

WillR(14)

-19.85

Bearish

Period

Simple value

Exponential vaue

685.76

690.09

10D

687.66

681.51

20D

660.44

662.12

50D

599.82

615.71

100D

553.18

569.91

About AKUMS DRUGS AND PHARMA L

ISIN

INE09XN01023

Sector Market Cap

₹ 10,772 Cr

Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.

AKUMS DRUGS AND PHARMA L Financial Highlights

Revenue: AKUMS DRUGS AND PHARMA L reported revenue of ₹4,487.75 crore in FY26 vs ₹4,170.28 crore in FY25. It showed an increase of 7.61% on a yearly basis.
Operating Profit: AKUMS DRUGS AND PHARMA L reported an operating profit of ₹382.10 crore in FY26 vs ₹345.25 crore in FY25. It showed an increase of 10.67% on a year-on-year basis.
Net Profit: AKUMS DRUGS AND PHARMA L reported a net profit of ₹256.40 crore in FY26 vs ₹343.78 crore in FY25. It showed a decrease of 25.42% on a yearly basis.

AKUMS DRUGS AND PHARMA L Quarterly Result Highlights

AKUMS DRUGS AND PHARMA L reported revenue of ₹1,193.17 crore in Mar 2026, compared with ₹1,193.92 crore in Dec 2025, representing a decrease of 0.06% on a quarter-on-quarter (QoQ) basis.
AKUMS DRUGS AND PHARMA L reported an operating profit of ₹121.22 crore in Mar 2026, compared with ₹99.57 crore in Dec 2025, representing an increase of 21.74% on a quarter-on-quarter (QoQ) basis.
AKUMS DRUGS AND PHARMA L reported a profit of ₹81.34 crore in Mar 2026, compared with ₹67.67 crore in Dec 2025, reflecting an increase of 20.20% on a QoQ basis.
The earnings per share (EPS) of AKUMS DRUGS AND PHARMA L stood at ₹16.67 during Mar 2026.